biosimilars

News

Roche's blockbuster breast cancer drug Herceptin

Sandoz strikes deal with EirGenix for Herceptin biosimilar

Sandoz has struck a deal with Taiwan-based EirGenix to market a late-stage biosimilar of Roche’s breast cancer blockbuster Herceptin.

Events

Partner Content

SMi’s 10th Annual Biosimilars Conference

Biosimilars Conference, London, Sept 2019

Partner Content

Save the date for SMi’s 10th Annual Biosimilars Conference 2...

Save the date for SMi’s 10th Annual Biosimilars Conf

Partner Content

Partner Content

J+D Forecasting expands theHub

News

CEO of Novartis' generics unit quits, sparking sale speculat...

Richard Francis is stepping down as CEO of Novartis’ generics and biosimilars division Sandoz at the end of March, sparking further speculation about the unit’s future.

Events

Pharma Forecasting Training with J+D Forecasting

Partner Content

Limited Places Available for J+D Forecasting Training Zurich

Limited places for J+D's Pharma Forecasting Training

Sandoz strikes deal with EirGenix for Herceptin biosimilar

SMi’s 10th Annual Biosimilars Conference

Save the date for SMi’s 10th Annual Biosimilars Conference 2...

J+D Forecasting expands theHub

CEO of Novartis' generics unit quits, sparking sale speculat...

Limited Places Available for J+D Forecasting Training Zurich

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

biosimilars

Editor's Picks